Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
On November 16, 2026, ENDRA Life Sciences Inc. (the “Company”)
issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is being
furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 2.02 of this Current Report on Form 8-K and
Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it
be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such filing.
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Exhibit
99.1
November
16, 2026
ENDRA
Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
ANN
ARBOR, Mich. (November 16, 2026) – ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”),
a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial
results for the third quarter ended September 30, 2026, and provided a business update.
Business
Update
During
the third quarter of 2026, ENDRA continued to manage its operating costs while continue to develop its third-generation ultrasound product.
At the same time, ENDRA is working to advance its proposed merger with Noble Africa LLC (“Noble Africa”), a subsidiary of
ASP Isotopes Inc. (NASDAQ: ASPI) (“ASP Isotopes”), and managed its operating resources in anticipation of the proposed transaction.
Pursuant
to the merger agreement announced on June 25, 2026, Noble Africa will become a wholly owned subsidiary of ENDRA, and ENDRA will be renamed
4K Resources Inc. The proposed transaction includes a concurrent private placement into Noble Africa that is expected to result in total
gross proceeds of approximately $50 million, and is expected to close immediately before the merger and the contribution of ASP Isotopes’
ownership interest in Renergen Limited (“Renergen”) to Noble Africa.
Completion
of the transaction remains subject to customary closing conditions, including stockholder approvals, effectiveness of the registration
statement on Form S-4, and compliance with applicable Nasdaq listing requirements.
Management
Commentary
“Our
focus during the third quarter remained on completing the proposed merger with Noble Africa while managing ENDRA’s operating resources
and liquidity to support transaction-related priorities,” said Alexander Tokman, Chairman and Chief Executive Officer of ENDRA
Life Sciences.
“The
proposed transaction represents an important strategic opportunity for our stockholders. We continue to work with our merger counterparties
to complete the remaining steps necessary to close the merger.”
Third
Quarter 2026 Financial Results
Cash
used in operations during the third quarter of 2026 was $1.8 million, compared with $1.2 million in the same period of 2025, primarily
reflecting higher professional fees associated with the proposed merger, digital asset management, and performance fees.
Operating
expenses in the third quarter of 2026 were $1.7 million, compared with $1.4 million in the same period of 2025. Research and development
expenses declined to approximately $176,000 from $432,000 in the comparable prior-year period, while general and administrative expenses
increased to $1.5 million from $893,000 in the prior-year period, primarily reflecting higher professional fees and costs associated
with the Company’s merger-related activities.
The
net loss for the third quarter of 2026 was $1.5 million, compared with a net loss of $1.6 million in the third quarter of 2025. The improvement
in net loss reflected approximately $187,000 of net other income in the third quarter of 2026, compared with approximately $225,000 of
net other expense in the prior-year period.
As
of September 30, 2026, ENDRA had $1.5 million in unrestricted cash, $3.4 million in restricted cash, and $1.3 million in digital assets.
The restricted cash relates to the Company’s May 2026 financing and associated contractual obligations.
About
ENDRA Life Sciences Inc.
ENDRA
Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to assess
tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS® is focused
on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated
steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic
tools. Our press releases and financial and other material information are routinely posted to and accessible on the Investors section
of our website, www.endrainc.com.
Important
Additional Information and Where to Find It
This
press release relates to the proposed merger and related transactions (the “Proposed Transactions”) involving ENDRA, ASP
Isotopes, Renergen and Noble Africa, and may be deemed to be solicitation material in respect of the Proposed Transactions. In connection
with the Proposed Transactions, ENDRA has filed relevant materials with the SEC, including a registration statement on Form S-4 (the
“Form S-4”) that contains a proxy statement (the “Proxy Statement”) and prospectus. This press release is not
a substitute for the Form S-4, the Proxy Statement or for any other document that ENDRA may file with the SEC and/or send to its stockholders
in connection with the Proposed Transactions. INVESTORS AND STOCKHOLDERS OF ENDRA ARE URGED TO READ THE FORM S-4, THE PROXY STATEMENT
AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS CAREFULLY
AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ENDRA, ASP ISOTOPES, RENERGEN,
NOBLE AFRICA, THE PROPOSED TRANSACTIONS AND RELATED MATTERS.
Investors
and stockholders will be able to obtain free copies of the Form S-4, the Proxy Statement and other documents filed by ENDRA and ASP Isotopes
with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. ENDRA’s Internet website address
is www.endrainc.com. ENDRA’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including
exhibits, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934,
as amended, are available free of charge through the investor relations page of its Internet website as soon as reasonably practicable
after it electronically files such material with, or furnishes such material to, the SEC.
Participants
in the Solicitation
ENDRA,
ASP Isotopes, Renergen, Noble Africa, and their respective directors and managers and certain of their executive officers and other members
of management may be deemed to be participants in the solicitation of proxies from ENDRA’s stockholders in connection with the
Proposed Transactions under the rules of the SEC. Information about ENDRA’s directors and executive officers, including a description
of their interests in ENDRA, is included in ENDRA’s most recent Annual Report on Form 10-K for the year ended December 31, 2025.
Information about ASP Isotopes’ directors and executive officers, including a description of their interests in ASP Isotopes, is
included in ASP Isotopes’ most recent Annual Report on Form 10-K for the year ended December 31, 2025. Additional information regarding
the persons who may be deemed participants in the proxy solicitations, including the directors and executive officers of Renergen, and
a description of their direct and indirect interests, by security holdings or otherwise, are also included in the Form S-4 and the Proxy
Statement and may be included in other relevant materials filed with the SEC. These documents can be obtained free of charge from the
sources indicated above.
No
Offer or Solicitation
This
press release is not intended to and does not constitute a solicitation of a proxy, consent or approval with respect to any securities
or in respect of the Proposed Transactions or an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation
to purchase or subscribe for any securities pursuant to the Proposed Transactions or otherwise, nor shall there be any sale, issuance
or transfer of securities in any jurisdiction in contravention of applicable law. No offering of securities shall be made except by means
of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable
law, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained,
the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of
the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission,
telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.
Forward-Looking
Statements
All
statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements—based
on certain assumptions and describing our future plans, strategies, and expectations—can generally be identified by the use of
terms such as “approximate,” “anticipate,” “attempt,” “believe,” “can,” “could,”
“estimate,” “expect,” “forecast,” “future,” “goal,” “hope,” “intend,”
“may,” “plan,” “possible,” “potential,” “project,” “seek,” “should,”
“will,” “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking
statements are express differently. Each forward-looking statement contained in this release is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or implied by such statement.
Applicable
risks and uncertainties include, among others: the risk that the conditions to the closing or consummation of the proposed merger with
Noble Africa and related transactions (the “Proposed Transactions”) are not satisfied, including the failure to timely obtain
approval of the Proposed Transactions from ENDRA stockholders, if at all; the risk that the proposed financings are not completed in
a timely manner, if at all; uncertainties as to the timing of the consummation of the Proposed Transactions and the ability of each of
ENDRA and Noble Africa to consummate the Proposed Transactions; risks related to ENDRA’s continued listing on Nasdaq until closing
of the Proposed Transactions and the combined company’s ability to remain listed following the closing of the Proposed Transactions;
risks related to ENDRA’s ability to correctly estimate its operating expenses and its expenses associated with the Proposed Transactions,
pending the closing of the Proposed Transactions, as well as uncertainties regarding the impact any delay in the closing would have on
the anticipated cash resources of ENDRA, and other events and unanticipated spending and costs that could reduce ENDRA’s cash resources;
risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to
consummate the Proposed Transactions; the occurrence of any event, change or other circumstance or condition that could give rise to
the termination of the merger agreement; the effect of the announcement or pendency of the Proposed Transactions on ENDRA’s or
Noble Africa’s business relationships, operating results and business generally; costs related to the Proposed Transactions; risks
related to the market price of ENDRA’s common stock relative to the value suggested by the Proposed Transactions; the outcome of
any legal proceedings that may be instituted against ENDRA, Noble Africa or any of their respective directors, managers, or officers
related to the Proposed Transactions; costs of the Proposed Transactions and unexpected costs, charges or expenses resulting from the
Proposed Transactions; changes in regulatory requirements and government incentives; risks associated with the possible failure to realize,
or that it may take longer to realize than expected, certain anticipated benefits of the Proposed Transactions, including with respect
to future financial and operating results, legislative, regulatory, political and economic developments, and those uncertainties and
factors; and the risk of involvement in litigation, including securities class action litigation, that could divert the attention of
the management of ENDRA or the combined company, harm the combined company’s business and may not be sufficient for insurance coverage
to cover all costs and damages, expectations regarding our treasury strategy and our ability to execute it successfully; our limited
commercial experience, limited cash resources, and history of losses; our ability to obtain adequate financing to fund operations in
the future; our ability to regain and maintain compliance with Nasdaq listing standards; delays or changes in regulatory requirements,
policies, or guidelines; the repeatability of clinical results across larger trial populations; potential delays in submitting required
regulatory applications or other submissions to, or receiving approvals from, the U.S. Food and Drug Administration (“FDA”)
or other regulatory agencies; our ability to obtain and maintain required CE mark certifications and secured required FDA and other governmental
approvals for our Thermo Acoustic Enhanced Ultrasound (“TAEUS®”) applications; our ability to develop commercially viable
products based on our TAEUS® technology; market acceptance of our technology; the effect of macroeconomic conditions on our business;
results of studies, which may be negative or inconclusive; our ability to secure and maintain development partners; reliance on third
parties, collaborations, strategic alliances, and licensing arrangements; the competitive landscape in the healthcare industry; our ability
to protect our intellectual property; changes in healthcare industry practices or reimbursement policies; our ability to comply with
regulations from federal, state, local, and foreign governmental agencies; risks related to shifts in regulatory, accounting, or tax
treatment affecting our treasury activities; the potential impact of any changes in financial reporting requirements; the risk that our
stock price may be affected by the performance or valuation of assets held in our treasury; a determination that we are an investment
company under the Investment Company Act of 1940; our ability to achieve profitability; our dependence on key members of management;
and other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition
and Results of Operations sections of the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on
Form 10-Q filed with the Securities and Exchange Commission.
You
should not rely on forward-looking statements as predictions of future events. Forward-looking statements in this press release speak
only as of the date of issuance, and ENDRA assumes no obligation to update such statements to reflect actual results or changes in expectations,
except as required by law.
ENDRA
Life Sciences Inc.
Condensed
Consolidated Balance Sheets
| | |
September 30, | | |
December 31, | |
| | |
2026 | | |
2025 | |
| Assets | |
(Unaudited) | | |
| |
| | |
| | |
| |
| Current Assets | |
| | |
| |
| Cash | |
$ | 1,516,523 | | |
$ | 762,365 | |
| Restricted cash | |
| 3,425,003 | | |
| - | |
| Prepaid expenses | |
| 109,590 | | |
| 205,604 | |
| Total Current Assets | |
| 5,051,116 | | |
| 967,969 | |
| Non-Current Assets | |
| | | |
| | |
| Fixed assets, net | |
| 35,603 | | |
| 42,516 | |
| Right of use assets | |
| 368,903 | | |
| 461,949 | |
| Prepaid expenses, long term | |
| - | | |
| 365,417 | |
| Digital Assets | |
| 1,261,490 | | |
| 2,009,960 | |
| Other assets | |
| 5,986 | | |
| 5,986 | |
| Total Assets | |
$ | 6,723,098 | | |
$ | 3,853,797 | |
| | |
| | | |
| | |
| Liabilities and Stockholders’ Equity | |
| | | |
| | |
| Current Liabilities | |
| | | |
| | |
| Accounts payable and accrued liabilities | |
$ | 492,272 | | |
$ | 621,578 | |
| Lease liabilities, current portion | |
| 143,452 | | |
| 129,378 | |
| Total Current Liabilities | |
| 635,724 | | |
| 750,956 | |
| | |
| | | |
| | |
| Long Term Liabilities | |
| | | |
| | |
| Lease liabilities | |
| 253,085 | | |
| 362,974 | |
| Warrant Liability | |
| 632,475 | | |
| 479,747 | |
| Total Long Term Liabilities | |
| 885,560 | | |
| 842,721 | |
| | |
| | | |
| | |
| Total Liabilities | |
| 1,521,284 | | |
| 1,593,677 | |
| Commitments and Contingencies | |
| - | | |
| - | |
| | |
| | | |
| | |
| Stockholders’ Equity | |
| | | |
| | |
| Series A Convertible Preferred Stock, $0.0001 par value; 10,000 shares authorized; 17.488 and 17.488 shares issued and outstanding, respectively | |
| - | | |
| - | |
| Series B Convertible Preferred Stock, $0.0001 par value; 1,000 shares authorized; no shares issued and outstanding | |
| - | | |
| - | |
| Series C Convertible Preferred Stock, $0.0001 par value; 100,000 shares authorized; no shares issued and outstanding | |
| - | | |
| - | |
| Common stock, $0.0001 par value; 1,000,000,000 shares authorized; 1,499,838 and 1,176,477 shares issued and outstanding, respectively | |
| 148 | | |
| 116 | |
| Additional paid in capital | |
| 118,356,529 | | |
| 112,725,513 | |
| Receivable related to employee equity awards | |
| (9,337 | ) | |
| - | |
| Accumulated deficit | |
| (113,145,526 | ) | |
| (110,465,509 | ) |
| Total Stockholders’ Equity | |
| 5,201,814 | | |
| 2,260,120 | |
| Total Liabilities and Stockholders’ Equity | |
$ | 6,723,098 | | |
$ | 3,853,797 | |
ENDRA
Life Sciences Inc.
Condensed
Consolidated Statement of Operations
(Unaudited)
| | |
Three Months Ended | | |
Three Months Ended | | |
Nine Months Ended | | |
Nine Months Ended | |
| | |
September 30, | | |
September 30, | | |
September 30, | | |
September 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Operating Expenses | |
| | |
| | |
| | |
| |
| Research and development | |
$ | 176,280 | | |
$ | 432,113 | | |
$ | 1,186,355 | | |
$ | 1,341,859 | |
| Sales and marketing | |
| - | | |
| 45,285 | | |
| 10,091 | | |
| 183,110 | |
| General and administrative | |
| 1,538,883 | | |
| 893,305 | | |
| 4,175,721 | | |
| 2,616,106 | |
| Total operating expenses | |
| 1,715,163 | | |
| 1,370,703 | | |
| 5,372,167 | | |
| 4,141,075 | |
| | |
| | | |
| | | |
| | | |
| | |
| Operating loss | |
| (1,715,163 | ) | |
| (1,370,703 | ) | |
| (5,372,167 | ) | |
| (4,141,075 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Other Income (Expenses) | |
| | | |
| | | |
| | | |
| | |
| Other income (expense) | |
| (28 | ) | |
| 42,018 | | |
| 278 | | |
| 79,474 | |
| Digital asset staking compensation | |
| 778 | | |
| - | | |
| 21,538 | | |
| - | |
| Unrealized gain on change in fair value of digital assets | |
| 168,049 | | |
| - | | |
| 2,197,117 | | |
| - | |
| Realized gain on change in fair value of digital assets | |
| 341,872 | | |
| - | | |
| 872,812 | | |
| - | |
| Digital asset management and performance fees | |
| (246,867 | ) | |
| - | | |
| (246,867 | ) | |
| - | |
| Changes in fair value of warrant liability | |
| (77,169 | ) | |
| (267,274 | ) | |
| (152,728 | ) | |
| 203,400 | |
| Total other income/(expense) | |
| 186,635 | | |
| (225,256 | ) | |
| 2,692,150 | | |
| 282,874 | |
| | |
| | | |
| | | |
| | | |
| | |
| Income/(loss) from operations before income taxes | |
| (1,528,528 | ) | |
| (1,595,959 | ) | |
| (2,680,017 | ) | |
| (3,858,201 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Provision for income taxes | |
| - | | |
| - | | |
| - | | |
| - | |
| | |
| | | |
| | | |
| | | |
| | |
| Net Income (Loss) | |
$ | (1,528,528 | ) | |
$ | (1,595,959 | ) | |
$ | (2,680,017 | ) | |
$ | (3,858,201 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Net income (loss) per share – basic and diluted | |
$ | (1.02 | ) | |
$ | (2.10 | ) | |
$ | (2.00 | ) | |
$ | (5.68 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Weighted average common shares – basic and diluted | |
| 1,499,838 | | |
| 761,218 | | |
| 1,342,470 | | |
| 679,210 | |
Company
Contact:
Investor Relations
investors@endrainc.com
www.endrainc.com
Investor
Relations Contact:
Vivian Cervantes
Alliance Advisors IR
973-873-7724
vcervantes@allianceadvisors.com